[1] «Iung B. Baron G., Butchart E.G .A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on valvular heart disease. Eur Heart J.-2003.-Vol 24.-P. 1231–1243.». [2] «Nishimura R. A., Otto C. M., Bonow R. O., Carabello B.A., Erwin III J. P., Guyton R. A., O’Gara P. T. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology/,» American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology.2014; 63(22):e57–185.. [3] «Otto C.M. Calcific aortic stenosis – time to look more closely at the valve. N. England J. Med 2008; 359:1395-8.». [4] «Nishimura R. A., Otto C. M,. Bonow R. O, Carabello B. A., Erwin J.P. III, Fleisher L.A., Jneid H. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease A Report of the American College of,» Cardiology/American Heart Association Task Force on Clinical Practice 48 Guidelines.Circulation. 2017;135:e1159–e1195. [5] «Baumgartner H, Hung J, Bermejo J., Chambers J.B., Edvardsen T., Goldstein S., Lancellotti P., Le Fevre M, Miller F., Otto C.M. Focus update on the echocardiographic assessment of aortic valve stenosis: EAE/ASE recommendations for clinical practice.,» Eur Heart J Cardiovasc Imaging 2017;18:254–275.. [6] «Henein M .Y. Valvular Heart Disease in Clinical Practice. Springer Science. 2010.». [7] «Carabello BA. Clinical practice: aortic stenosis. N. Engl J Med 2002; 346:677– 82.». [8] «Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M.Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-11.». [9] «Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.,» J Am Coll Cardiol 2020; Dec 17; doi: 10.1161/CIR.0000000000000932. Epub 2020 Dec 17. [10] «Rosenhek R., Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G.,Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000; 343:611– 617.». [11] «Bergler-Klein J, Gyongyosi M, Maurer G. The role of biomarkers in valvular heart disease: focus on natriuretic peptides. Can J Cardiol 2014;30:1027–1034.106:2224–30.». [12] «Baumgartner H., Falk V., Bax J.J, Bonis M.., Hamm C., Per Johan Holm P.JJ., Iung B. , Lancellotti P., Lansac E. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. The Task Force for the Management of Valvular Heart Disease,» of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal (2017) 38, 2739–2791. [13] «Otto CM, Burwash I.G, Legget M.E, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997;95:2262–70.». [14] «Pellikka P.A, Sarano M.E, Nishimura R.A, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 2005; 111:3290 –5.». [15] «Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael Böhm, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment,» of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC,, European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3599–3726, https://doi.org/10.1093/eurheartj/ehab368. [16] «Alec Vahanian, Friedhelm Beyersdorf, Fabien Praz, Milan Milojevic, Stephan Baldus, Johann Bauersachs, Davide Capodanno, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management,» of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS),, European Heart Journal, 2021;, ehab395, https://doi.org/10.1093/eurheartj/ehab395. [17] «Monin J.L, Quere J.P, Monchi M, et al. Low-gradient aortic stenosis: operative risk 49 stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. Circulation 2003; 108:319 –24.». [18] «Levy F, Laurent M, Monin J.L, Maillet J.M, Pasquet A, Le Tourneau T, Petit-Eisenmann H, Gori M, Jobic Y, Bauer F, Chauvel C, Leguerrier A, Tribouilloy C. Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification,» and long-term outcome: a European multicenter study. J Am Coll Cardiol 2008;51:1466–1472.. [19] «Das P, Rimington H., Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur Heart J 2005; 26:1309 –13.». [20] «Henri C, Pierard LA, Lancellotti P, Mongeon Р, Pibarot P, Basmadjian AJ. Exercise testing and stress imaging in valvular heart disease. Can J Cardiol 2014; 30: 1012–1026.». [21] «Azevedo C.F, Nigri M, Higuchi M.L, Pomerantzeff P.M, Spina G.S, Sampaio R..O, Tarasoutchi F., Grinberg M., Rochitte C.E. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with,» severe aortic valve disease. J Am Coll Cardiol 2010;56:278–287. . [22] «Cueff C, Serfaty JM, Cimadevilla C, Laissy JP, Himbert D, Tubach F, Duval X, Iung B., Enriquez-Sarano M., Vahanian A., Messika-Zeitoun D. Measurement of aortic valve calcification using multislice computed tomography: correlation with haemodynamic,» severity of aortic stenosis and clinical implication for patients with low ejection fraction. Heart 2011;97:721–726. [23] «Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf J, Araoz PA, Michelena HI, Cueff C, Larose E, Capoulade R, Vahanian A, Enriquez-Sarano M. The complex nature of discordant severe calcified aortic valve disease grading: new insights from,» combined Doppler echocardiographic and computed tomographic study. J Am Coll Cardiol 2013; 62: 2329– 2338.. [24] «Gerber M.A, Baltimore R.S, Eaton C.B, Gewitz M, Rowley A.H, Shulman S.T, Taubert K.A. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic,» Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care, and Outcomes Research.. [25] «Rossebo A.B, Pedersen T.R, Boman K, Brudi P, Chambers J.B, Egstrup K, Gerdts E, GohlkeBarwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators. Intensive lipid lowering with,» simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343–1356.. [26] «Cowell S.J, Newby D.E, Prescott R.J, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl Med 2005; 352:2389 – 97.». [27] «Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Committee RAS, Investigators.,» Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014;35:3377-3385. . [28] «Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, 50 Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Apixaban in comparison with warfarin in patients with atrial fibrillation and,» valvular heart disease: findings from the Apixaban for Reductionin Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)trial. Circulation 2015;132:624-632. . [29] «Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L. Comparison of dabiga- tran and warfarin in patients with atrial fibrillation and,» valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation 2016;134:589-598. . [30] «De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 2017;69:1372-1382.». [31] «Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA. EACTS Audit and Guidelines Committee. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008;34:73–92.». [32] «Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation1994;89:635-641.». [33] «Heneghan C, Ward A, Perera R, Self-Monitoring Trialist C, Bankhead C, Fuller A, Stevens R, Bradford K, Tyndel S, Alonso-Coello P, Ansell J, Beyth R, Bernardo A, Christensen TD, Cromheecke ME, Edson RG, Fitzmaurice D, Gadisseur AP, Garcia-Alamino JM,,» Gardiner C, Hasenkam JM, Jacobson A, Kaatz S, Kamali F, Khan TI, Knight E, Kortke H, Levi M, Matchar D, Menendez-Jandula B, Rakovac I, Schaefer C, Siebenhofer A, Souto JC, Sunderji R, Gin K, Shalansky K, Voller H, Wagner O,, Zittermann A. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012;379:322-334.. [34] «Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS, Douglas PS, Peterson ED, DEcIDE AVR Research Team. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac,» Surgery National Database. J Am Coll Cardiol 2012;60:971-977.. [35] «Merie C, Kober L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J, Torp-Pedersen C. Association of warfarin therapy duration after bioprostheticaortic valve replacement with risk of mortality, thromboembolic complications and bleeding.,» JAMA 2012;308:2118-2125.. [36] «Christersson C, James SK, Lindhagen L, Ahlsson A, Friberg O, Jeppsson A, Stahle E. Comparison of warfarin versus antiplatelet therapy after surgical bioprosthetic aortic valve replacement. Heart 2020;106:838-844.». [37] «Rafiq S, Steinbruchel DA, Lilleor NB, Moller CH, Lund JT, Thiis JJ, Kober L, Olsen PS. Antithrombotic therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial. Thromb Res 2017;150:104-110.». [38] «Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2013:CD003464.». [39] «Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L, TorpPedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin,,» aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433.. 51 [40] «Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N.,» Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial. J Am Coll Cardiol 2015;65:1619–1629.. [41] «Raffaele De Caterina, Stefan Agewall, Felicita Andreotti et all. Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week, European Heart Journal,,» Volume 43, Issue 37, 1 October 2022, Pages 3512–3527, https://doi.org/10.1093/eurheartj/ehac294. [42] «Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van‘t Hof AW, ten Berg JM, WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking,» oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107–1115.. [43] «Thourani V.H, Suri R.M, Gunter R.L, Sheng S, O’Brien S.M, Ailawadi G, Szeto W.Y, Dewey T.M, Guyton R.A, Bavaria J.E, Babaliaros V, Gammie J.S, Svensson L, Williams M, Badhwar V, Mack M.J.,» Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients. Ann Thorac Surg 2015;99:55–61.. [44] «Reardon M.J, VanMieghem N.M, PopmaJ.J, Kleiman N.S, Sondergaard L, MumtazM, AdamsD.H, DeebG.M, MainiB, GadaH, ChetcutiS, GleasonT, HeiserJ, LangeR, MerhiW, OhJK, SURTAVIInvestigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk,» patients. N Engl J Med 2017;376:1321–1331.. [45] «Zlotnick D.M, Ouellette M.L, Malenka D.J, De Simone J.P, Leavitt B.J, Helm R.E, Olmstead E.M, Costa S.P, DiScipio A.W, Likosky D.S, Schmoker J.D, Quinn R.D. Northern New England Cardiovascular Disease Study Group.,» Effect of preoperative pulmonary hypertension on outcomes in patients with severe aortic stenosis following surgical aortic valve replacement. Am J Cardiol 2013;112:1635–1640.. [46] «Mangner N, Stachel G, Woitek F, Haussig S, Schlotter F, Hollriegel R, Adam J,Lindner A, Mohr FW, Schuler G, Kiefer P, Leontyev S, Borger MA, Thiele H, Holzhey D, Linke A.,» Predictors of mortality and symptomatic outcome of patients with low-flow severe aortic stenosis undergoing transcatheter aortic valve replacement. J Am Heart Assoc 2018;7:e007977.. [47] «Iung B, Laouenan C, Himbert D, Eltchaninoff H, Chevreul K, Donzeau-Gouge P, Fajadet J, Leprince P, Leguerrier A, Lievre M, Prat A, Teiger E, Laskar M, Vahanian A, Gilard M, FRANCE 2 Investigators. Predictive factors of early mortality after,» transcatheter aortic valve implantation: individual risk assessment using a simple score. Heart 2014;100:1016-1023. . [48] «Edwards FH, Cohen DJ, O’Brien SM, Peterson ED, Mack MJ, Shahian DM, Grover FL, Tuzcu EM, Thourani VH, Carroll J, Brennan JM, Brindis RG, Rumsfeld J, Holmes DR, Jr., Steering Committee of the Society of Thoracic Surgeons/,» American College of Cardiology Transcatheter Valve Therapy R. Development and validation of a risk prediction model for inhospital mortality after transcatheter aortic valve replacement. JAMA Cardiol 2016;1:46-52. . [49] «Arnold SV, Reynolds MR, Lei Y, Magnuson EA, Kirtane AJ, Kodali SK, Zajarias A, Thourani VH, Green P, Rodes-Cabau J, Beohar N, Mack MJ, Leon MB, Cohen DJ, PARTNER 52 Investigators.,» Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation 2014;129:2682- 2690. . [50] «Afilalo J. The Clinical Frailty Scale: Upgrade your eyeball test. Circulation 2017;135:2025- 2027.». [51] «Kundi H, Popma JJ, Reynolds MR, Strom JB, Pinto DS, Valsdottir LR, Shen C, Choi E, Yeh RW. Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort. Eur Heart J 2019;40:2231-2239.». [52] «Hosler QP, Maltagliati AJ, Shi SM, Afilalo J, Popma JJ, Khabbaz KR, Laham RJ, Guibone K, Kim DH. A practical two-stage frailty assessment for older adults undergoing aortic valve replacement. J Am Geriatr Soc 2019;67:2031-2037.». [53] «Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD. Management of frailty: opportunities, challenges, and future directions. Lancet 2019;394:1376-1386.». [54] «Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 1983;31:721-727.». [55] «Steiner JM, Cooper S, Kirkpatrick JN. Palliative care in end-stage valvular heart disease. Heart 2017;103:1233-1237.». [56] «DeebG.M, ReardonM.J, ChetcutiS, PatelH.J, GrossmanP.M, YakubovS.J, KleimanN.S, CoselliJ.S, GleasonT.G, LeeJ.S, HermillerJ.BJr, HeiserJ, MerhiW,ZornG.L 3rd, TadrosP, RobinsonN, PetrossianG, HughesGC, HarrisonJ.K,MainiB, MumtazM, ConteJ,,» ResarJ, AharonianV, PfefferT, OhJK, QiaoH, AdamsD.H, PopmaJ.J, CoreValveUSClinicalInvestigators. 3-year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol 2016;67:2565–2574.. [57] «Lancellotti P, Magne J, Dulgheru R, Clavel MA, Donal E, Vannan MA, Chambers J, Rosenhek R, Habib G, Lloyd G, Nistri S, Garbi M, Marchetta S, Fattouch K, Coisne A, Montaigne D, Modine T, Davin L, Gach O, Radermecker M, Liu S, Gillam L, Rossi A, Galli E,,» Ilardi F, Tastet L, Capoulade R, Zilberszac R, Vollema EM, Delgado V, Cosyns B, Lafitte S, Bernard A, Pierard LA, Bax JJ, Pibarot POury C., Outcomes of patients with asymptomatic aortic stenosis followed up in heart valve clinics. JAMA Cardiol 2018;3:1060-1068.. [58] «Dahl JS, Eleid MF, Michelena HI, Scott CG, Suri RM, Schaff HV, Pellikka PA. Effect of left ventricular ejection fraction on postoperative outcome in patients with severe aortic stenosis undergoing aortic valve replacement.,» Circ Cardiovasc Imaging 2015;8:e002917.. [59] «Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, Murata K, Kitai T, Kadota K, Izumi C, Nakatsuma K, Sasa T, Watanabe H, Kuwabara Y, Makiyama T, Ono K, Shizuta S, Kato T, Saito N, Minatoya K, Kimura T,,» CURRENTAS Registry Investigators. Prognostic impact of left ventricular ejection fraction in patients with severe aortic stenosis. JACC Cardiovasc Interv 2018;11:145-157.. [60] «Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, Binder T,Pacher R, Maurer G, Baumgartner H. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004; 109:2302–2308.». [61] «Bohbot Y, Kowalski C, Rusinaru D, Ringle A, Marechaux S, Tribouilloy C. Impact of mean transaortic pressure gradient on long-term outcome in patients with severe aortic stenosis and preserved left ventricular ejection fraction. J Am Heart Assoc 2017;6». 53 [62] «Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, Aggarval S, Araoz PA, Michelena HI, Cueff C, Larose E, Miller JD, Vahanian A, Enriquez- Sarano M. Impact of aortic valve calcification, as measured by MDCT, on survival in patients with,» aortic stenosis: results of an international registry study. J Am Coll Cardiol 2014;64:1202- 1213. . [63] «Pawade T, Clavel MA, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L, Renard C, Gun M, Jenkins WSA, Macron L, Sechrist JW, Lacomis JM, Nguyen V, Galian Gay L, Cuellar Calabria H,,» Ntalas I, Cartlidge TRG, Prendergast B, Rajani R, Evangelista A, Cavalcante JL, Newby DE, Pibarot P, Messika Zeitoun D, Dweck MR. Computed tomography aortic valve calcium scoring in patients with aortic stenosis. Circ Cardiovasc Imaging 2018;11:e007146. . [64] «Clavel MA, Malouf J, Michelena HI, Suri RM, Jaffe AS, Mahoney DW, Enriquez- Sarano M. B-type natriuretic peptide clinical activation in aortic stenosis: impacton long-term survival. J Am Coll Cardiol 2014;63:2016-2025.». [65] «Nishimura RA, O’Gara PT, Bavaria JE, Brindis RG, Carroll JD, Kavinsky CJ, Lindman BR, Linderbaum JA, Little SH, Mack MJ, Mauri L, Miranda WR, Shahian DM, Sundt TM, 3rd. 2019 AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care Document: a proposal,» to optimize care for patients with valvular heart disease: a joint report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions,, and Society of Thoracic Surgeons. J Am Coll Cardiol 2019;73:2609- 2635. [66] «Lindman BR, Arnold SV, Bagur R, Clarke L, Coylewright M, Evans F, Hung J, Lauck SB, Peschin S, Sachdev V, Tate LM, Wasfy JH, Otto CM. Priorities for patient-centered research in valvular heart disease:,» : a report from the National Heart, Lung, and Blood Institute Working Group. J Am Heart Assoc 2020;9:e015975. . [67] «Hejjaji V, Cohen DJ, Carroll JD, Li Z, Manandhar P, Vemulapalli S, Nelson AJ, Malik AO, Mack MJ, Spertus JA, Arnold SV. Practical application of patient- reported health status measures for transcatheter valve therapies:,» insights from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry. Circ Cardiovasc Qual Outcomes2021;14:e007187.. [68] «Goldstone AB, Chiu P, Baiocchi M, Lingala B, Patrick WL, Fischbein MP, Woo YJ. Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement. N Engl J Med 2017;377:1847-1857.». [69] «Diaz R, Hernandez-Vaquero D, Alvarez-Cabo R, Avanzas P, Silva J, Moris C, Pascual I. Long-term outcomes of mechanical versus biological aortic valve prosthesis: systematic review and meta-analysis. J Thorac Cardiovasc Surg 2019;158:706-714.». [70] «Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Heart 2019;105:1432- 1436.». [71] «Duan L, Doctor JN, Adams JL, Romley JA, Nguyen LA, An J, Lee MS.Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves. Am J Cardiol 2021;146:22-28.». [72] «Pasciolla S, Zizza LF, Le T, Wright K. Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements.Clin Drug Investig 2020;40:839-845.». [73] «Russo V, Carbone A, Attena E, Rago A, Mazzone C, Proietti R, Parisi V, Scotti A, Nigro G, Golino P, D’Onofrio A. Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart,» valves. Clin Ther 2019;41:2549-2557.. [74] «Otto C.M, Mickel M.C, Kennedy JW, et al. Three-year outcome after balloon aortic valvuloplasty: insights into prognosis of valvular aortic stenosis. Circulation 1994; 89:642– 50.». [75] «Lieberman EB, Bashore TM, Hermiller JB, et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol 1995; 26:1522– 8.». [76] «Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ,,» PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187-2198. . [77] «Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, Webb JG, Douglas PS, Anderson WN, Blackstone EH, Kodali SK, Makkar RR, Fontana GP, Kapadia S, Bavaria J, Hahn RT, Thourani VH, Babaliaros V, Pichard A, Herrmann HC, Brown DL, Williams M,,» Akin J, Davidson MJ, Svensson LG, PARTNER 1 trial Investigators. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial, Lancet 2015;385:2477-2484. [78] «Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J, Jr., Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B,,» Mumtaz M, Chenoweth S, Oh JK, Investigators USCC.Transcatheter aortic-valve replacement with a selfexpanding prosthesis. N Engl J Med 2014;370:1790-1798. . [79] «Thyregod HG, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, Chang Y, Franzen OW, Engstrom T, Clemmensen P, Hansen PB, Andersen LW, Olsen PS, Sondergaard L.,» Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the All-Comers NOTION randomized clinical trial. J Am Coll Cardiol 2015;65:2184-2194. . [80] «Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL,,» Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG, PARTNER 2, Investigators. Transcatheter or surgical aorticvalve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609-1620. . [81] «Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG, Yoon SH, Trento A, Svensson LG, Herrmann HC, Szeto WY, Miller DC, Satler L, Cohen DJ, Dewey TM, Babaliaros V, Williams MR, Kereiakes DJ, Zajarias A, Greason KL, Whisenant BK,,» Hodson RW, Brown DL,Fearon WF, Russo MJ, Pibarot P, Hahn RT, Jaber WA, Rogers E, Xu K, Wheeler J, Alu MC, Smith CR, Leon MB, Investigators P. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med 2020;382:799-809. . 55 [82] «Thyregod HGH, Ihlemann N, Jorgensen TH, Nissen H, Kjeldsen BJ, Petursson P, Chang Y, Franzen OW, Engstrom T, Clemmensen P, Hansen PB, Andersen LW, Steinbruchel DA, Olsen PS, Sondergaard L.,» Five-year clinical and echocardio- graphic outcomes from the Nordic Aortic Valve Intervention (NOTION) randomized clinical trial in lower surgical risk patients.Circulation 2019;139:2714- 2723. . [83] «Siontis GC, Praz F, Pilgrim T, Mavridis D, Verma S, Salanti G, Sondergaard L, Juni P, Windecker S. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of,» randomized trials. Eur Heart J 2016;37:3503-3512. . [84] «Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL,Babaliaros V,,» , Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR, PARTNER 3 Investigators., Transcatheter aortic-valve replacement with a balloon-xpandable valve in low- risk patients. N Engl J Med 2019;380:1695-1705. . [85] «Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL, 3rd, Forrest JK, Tchetche D, Resar J, Walton A, Piazza N,» Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ, Evolut Low Risk Trial Investigators., Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019;380:1706-1715. . [86] «Siontis GCM, Overtchouk P, Cahill TJ, Modine T, Prendergast B, Praz F, Pilgrim T, Petrinic T, Nikolakopoulou A, Salanti G, Sondergaard L, Verma S, Juni P, Windecker S,» Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J 2019;40:3143- 3153. . [87] «Leon MB, Mack MJ, Hahn RT, Thourani VH, Makkar R, Kodali SK, Alu MC, Madhavan MV, Chau KH, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Blanke P, Leipsic JA, Williams MR, McCabe JM,,» Brown DL, Babaliaros V, Goldman S, Herrmann HC, Szeto WY, Genereux P, Pershad A, Lu M, Webb JG, Smith CR, Pibarot P, PARTNER 3 Investigators, Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol 2021;77:1149-1161.. [88] «Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, Smalling R, Lim S, Malaisrie SC, Kapadia S, Szeto WY, Greason KL, Kereiakes D, Ailawadi G, Whisenant BK, Devireddy C, Leipsic J, Hahn RT, Pibarot P,,» Weissman NJ, Jaber WA, Cohen DJ, Suri R, Tuzcu EM, Svensson LG, Webb JG, Moses JW, Mack MJ, Miller DC, Smith CR, Alu MC, Parvataneni R, D’Agostino RB, Jr., Leon MB., Mack MJ, Miller DC, Smith CR, Alu MC, Parvataneni R, D’Agostino RB, Jr., Leon MB. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet 2016;387:2218-2225. . [89] «Gleason TG, Reardon MJ, Popma JJ, Deeb GM, Yakubov SJ, Lee JS, Kleiman NS, Chetcuti S, Hermiller JB, Jr., Heiser J, Merhi W, Zorn GL, 3rd, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte JV, Mumtaz M, Oh JK, Huang J,,» Adams DH, CoreValve US Pivotal High Risk Trial Clinical Investigators. 5-Year outcomes of self-expanding transcatheter versus surgical aortic valve replacement in high-risk patients. J Am Coll Cardiol 56 2018;72:2687-2696.. [90] «LeonM.B, SmithC.R, MackM, MillerD.C, MosesJ.W, SvenssonL.G, TuzcuE.M, WebbJ.G, FontanaG.P, MakkarR.R, BrownD.L, BlockP.C, GuytonR.A, PichardA.D, BavariaJ.E, HerrmannH.C, DouglasP.S, PetersenJ.L, AkinJ.J, AndersonW.N, WangD, PocockS; PARTNER Trial,» PARTNERTrialInvestigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597 – 1607.. [91] «Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, Cribier A, De Jaegere P, Fournial G, Kappetein A.P, Kovac J, Ludgate S, Maisano F, Moat N, Mohr F.,» Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of, Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J. 2008;29:1463 – 1470. [92] «Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S,Salamon R. European system for cardiac operative risk evaluation(EuroSCORE). Eur J Cardiothorac Surg 1999;16:9 –13.». [93] «Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, Fischbein M, Szeto WY, Lim S, Greason KL,,» Teirstein PS, Malaisire SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A, Wang D, Akin JJ, Anderson WN, and Leon MB for the PARTNER Trial Investogators., Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012;366:1686-95.. [94] Рыбка М.М., Хинчагов Д.Я., Мумладзе К.В., Никулкина Е.С. Под ред. Л.А.Бокерия. Протоколы анестезиологического обеспечения рентгенэндоваскулярных и диагностических процедур, выполняемых у кардиохирургических пациентов различных возрастных групп., Методические рекомендации. М.: НЦССХ им. А. Н. Бакулева РАМН; 2018.. [95] «Landoni G., et al. Volatile Anesthetics versus Total Intravenous Anesthesia for Cardiac Surgery// N Engl J Med. 2019. – Vol. 380(13). – Р. 1214-1225». [96] «Sardo S, Osawa EA, Finco G, Gomes Galas FRB, de Almeida JP, Cutuli SL, Frassanito C, Landoni G, Hajjar LA. Nitric Oxide in Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials. J Cardiothorac Vasc Anesth. 2018 Dec;32(6):2512-2519.,» doi: 10.1053/j.jvca.2018.02.003.. [97] «Приказ Министерства здравоохранения РФ от 31 июля 2020 г. N 778н "О Порядке организации медицинской реабилитации взрослых" Зарегистрировано в Минюсте РФ 25 сентября 2020 г. Регистрационный № 60039 https://www.garant.ru/products/ipo/prime/doc/74581688». [98] «Butchart E. G., Gohlke-BaЁrwolf C., Antunes M.J. Tornos P., De Caterina R, Cormier B. Prendergast B., Iung B. Recommendations for the management of patients after heart valve surgery. European Heart Journal (2005) 26, 2463–2471». [99] «Ambrosetti M., Abreu A., Corrà U., et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update.,» A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. European Journal of Preventive Cardiology. 2021; 28: 460-495. doi: 10.1177/2047487320913379.. [100] «Eichler S., Salzwedel A., Reibis R., et al. Multicomponent cardiac rehabilitation in patients 57 after transcatheter aortic valve implantation: Predictors of functional and psychocognitive recovery. Eur J Prev Cardiol. 2017;24:257–264.,» doi: 10.1177/2047487316679527.. [101] «Patrick D., Savage M.S., Jason L., et al. Cardiac Rehabilitation after Heart Valve Surgery: Comparison with Coronary Artery Bypass Grafting Patients. J Cardiopulm Rehabil Prev. 2015;35(4):231–237. doi:10.1097/HCR.0000000000000104.». [102] «Hansen T.B., Zwisler A.D., Berg S.K., et al. Cost-utility analysis of cardiac rehabilitation after conventional heart valve surgery versus usual care. Eur J Prev Cardiol. 2017;24(7):698- 707. doi:10.1177/2047487317689908.». [103] «Gladkova M.A., Kassirsky GI. Topical problems in rehabilitation following valve replacement. CorVasa. 1984;26:394-399.». [104] «Anderson L., Sharp G.A., Norton R.J., et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database of Systematic Reviews. 2017;6:CD007130. doi: 10.1002/14651858.CD007130.». [105] «Thomas R.J., Beatty A.L., Beckle T.M., et al. Home-based cardiac rehabilitation: a scientific statement from the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American,» College of Cardiology. Circulation. 2019;140:e69-e89.doi:10.1161/CIR.0000000000000663.. [106] «Kraal J.J., Van den Akker-Van Marle M.E., Abu-Hanna A., et al. Clinical and costeffectiveness of home-based cardiac rehabilitation compared to conventional, centre-based cardiac rehabilitation:,» : results of the FIT@Home study. Eur J Prev Cardiol. 2017;24(12):1260-1273.doi:10.1177/2047487317710803.. [107] «Федеральный закон от 29.07.2017 N 242-ФЗ "О внесении изменений в отдельные законодательные акты Российской Федерации по вопросам применения информационных технологий в сфере охраны здоровья" https://www.garant.ru/products/ipo/prime/doc/716328 44/.». [108] «Thomas R.J., Balady G., Banka G., et al. 2018 ACC/AHA Clinical Performance and Quality Measures for Cardiac Rehabilitation: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.,» J Am Coll Cardiol. 2018;71(16):1814-1837. doi:10.1016/j.jacc.2018.01.004. . [109] Иванова Г.Е., Мельникова Е.В., Шмонин А.А., Вербицкая Е.В., Аронов Д.М., Белкин А.А., Беляев А.Ф., Бодрова Р.А., Бубнова М.Г., Буйлова Т.В., Мальцева М.Н., Мишина И.Е., Нестерин К.В., Никифоров В.В.,Прокопенко С.В., Сарана А.М., Стаховская Л.В., Суворов А, Хасанова Д.Р., Цыкунов М.Б. Применение международной классификации функционирования в процессе медицинской реабилитации. Вестник восстановительной медицины. 2018: (88):2-77. eLIBRARY ID: 36486374. [110] «https://www.icf-research-branch.org/download/send/12- cardiovascularandrespiratoryconditions/156-brief-icf-core-set-for-cardiopulmonary-conditionsin-acute-care». [111] «https://www.icf-research-branch.org/download/send/12- cardiovascularandrespiratoryconditions/162-brief-icf-core-set-for-cardiopulmonary-conditionsin-post-acute-care». [112] «Ambrosetti M., Abreu A., Cornelissen V., et al. Delphi consensus recommendations on how to provide cardiovascular rehabilitation in the COVID-19 era. Eur J Prev Cardiol. 58 2021;28(5):541-557. doi: 10.1093/eurjpc/zwaa080. PMID: 33624042;». [113] «Mezzani A., Hamm L.F., Jones A.M., et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: A joint position statement of the European association for cardiovascular prevention and rehabilitation,,» the American association of cardiovascular and pulmonary rehabilitation and the Canadian association of cardiac rehabilitation. Eur J Prev Cardiol. 2013;20:442–467.doi:10.1177/2047487312460484. . [114] «Fletcher G.F., Ades P.A., Kligfield P., et al. Exercise Standards for Testing and Training A Scientific Statement From the American Heart Association. Circulation. 2013;128:873-934. doi:10.1161/CIR.0b013e31829b5b44». [115] «Opasich C., De Feo S., Pinna G.D., et al. Distance walked in the 6-minute test soon after cardiac surgery: toward an efficient use in the individual patient. Chest. 2004;126(6):1796- 1801. doi:10.1378/chest.126.6.1796.». [116] «Mok M., Nombela-Franco L., Urena M., et al. Prognostic value of exercise capacity as evaluated by the 6-minute walk test in patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol. 2013;61(8):897-898.,» doi:10.1016/j.jacc.2012.10.050.. [117] «Nechwatal R.M. Cardiac rehabilitation after surgical and transcatheter valve replacement and repair. Dtsch Z Sportmed. 2018;69:285-292. doi:10.5960/dzsm.2018.343». [118] Кардиология: национальное руководство: под ред. Е. В. Шляхто. 2-е изд., перераб. И доп. М.: ГЭОТАР-Медиа, 2015. 800 с. [119] Руководство по кардиологии: под ред. акад. Е. И. Чазова. В 4 т. М.: Издательский дом «Практика», 2014.. [120] McMurray J.J.V., Solomon S.D., Inzucchi S.E., Køber L., Kosiborod M.N., Martinez F.A., Ponikowski P., Sabatine M.S., Anand I.S., Bělohlávek J., Böhm M., Chiang C.-E., Chopra V.K., de Boer R.A., Desai A.S., Diez M., Drozdz J., Dukát A., Ge J., Howlett J.G., Katova T., Kitakaze M., Ljungman C.E.A., Merkely B., Nicolau J.C., O’Meara E., Petrie M.C., Vinh P.N, Schou M., Tereshchenko S., Verma S., Held C., DeMets D.L., Docherty K.F., Jhund P.S., Bengtsson O., Sjöstrand M., Langkilde A.-M. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. September 19, 2019. doi: 10.1056/NEJMoa1911303. [121] Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Bohm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPERORReduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-1424. [122] Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9.